The Pine Tree, News for Calaveras County and Beyond Weather
Amador Angels Camp Arnold Bear Valley Copperopolis Murphys San Andreas Valley Springs Moke Hill/West Point Tuolumne
Business Directory
Weather & Roads
Real Estate
Weekly & Grocery Ads
Life & Style
Law Enforcement
Wine News
Health & Fitness
Home & Garden
Food & Dining
Religion & Faith
Frogtown USA
Legal Notices
Free Classifieds
Letters to the Editor
About Us

Search Announcements

Log In


Remember Me

Posted by: thepinetree on 11/09/2020 07:47 AM Updated by: thepinetree on 11/09/2020 07:47 AM
Expires: 01/01/2025 12:00 AM

COVID-19 Vaccine Candidate Found to be More than 90% Effective in Preventing COVID-19

New York, NY & Mainz, DE-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.

“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule. As the study continues, the final vaccine efficacy percentage may vary. The DMC has not reported any serious safety concerns and recommends that the study continue to collect additional safety and efficacy data as planned. The data will be discussed with regulatory authorities worldwide.

“I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor,” added Bourla. “We could not have come this far without the tremendous commitment of everyone involved.”

“The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort,” said Prof. Ugur Sahin, BioNTech co-founder and CEO. “When we embarked on this journey 10 months ago this is what we aspired to achieve. Especially today, while we are all in the midst of a second wave and many of us in lockdown, we appreciate even more how important this milestone is on our path towards ending this pandemic and for all of us to regain a sense of normality. We will continue to collect further data as the trial continues to enroll for a final analysis planned when a total of 164 confirmed COVID-19 cases have accrued. I would like to thank everyone who has contributed to make this important achievement possible.”

The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued. The study also will evaluate the potential for the vaccine candidate to provide protection against COVID-19 in those who have had prior exposure to SARS-CoV-2, as well as vaccine prevention against severe COVID-19 disease. In addition to the primary efficacy endpoints evaluating confirmed COVID-19 cases accruing from 7 days after the second dose, the final analysis now will include, with the approval of the FDA, new secondary endpoints evaluating efficacy based on cases accruing 14 days after the second dose as well. The companies believe that the addition of these secondary endpoints will help align data across all COVID-19 vaccine studies and allow for cross-trial learnings and comparisons between these novel vaccine platforms. The companies have posted an updated version of the study protocol at

Pfizer and BioNTech are continuing to accumulate safety data and currently estimate that a median of two months of safety data following the second (and final) dose of the vaccine candidate – the amount of safety data specified by the FDA in its guidance for potential Emergency Use Authorization – will be available by the third week of November. Additionally, participants will continue to be monitored for long-term protection and safety for an additional two years after their second dose.

Along with the efficacy data generated from the clinical trial, Pfizer and BioNTech are working to prepare the necessary safety and manufacturing data to submit to the FDA to demonstrate the safety and quality of the vaccine product produced.

Based on current projections we expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.

Pfizer and BioNTech plan to submit data from the full Phase 3 trial for scientific peer-review publication.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at In addition, to learn more, please visit us on and follow us on Twitter at @Pfizer and @Pfizer NewsLinkedInYouTube and like us on Facebook at

Pfizer Disclosure Notice

The information contained in this release is as of November 9, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine, the BNT162 mRNA vaccine program, and modRNA candidate BNT162b2 (including qualitative assessments of available data, potential benefits, expectations for clinical trials, anticipated timing of clinical trial readouts and regulatory submissions and anticipated manufacturing, distribution and supply), that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary and interim data, (including the Phase 3 interim data that is the subject of this release), including the possibility of unfavorable new preclinical or clinical trial data and further analyses of existing preclinical or clinical trial data; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications; whether regulatory authorities will be satisfied with the design of and results from these and future preclinical and clinical studies; whether and when any biologics license and/or emergency use authorization applications may be filed in any jurisdictions for BNT162b2 or any other potential vaccine candidates; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine candidate’s benefits outweigh its known risks and determination of the vaccine candidate’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners or third-party suppliers; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine candidate’s ultra-low temperature formulation and attendant storage, distribution and administration requirements, including risks related to handling after delivery by Pfizer; the risk that we may not be able to successfully develop non-frozen formulations; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or have access to logistics or supply channels commensurate with global demand for any potential approved vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine candidate within the projected time periods indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at and

About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma, and Pfizer. For more information, please visit

BioNTech Forward-looking statements

This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our Phase 2/3 trial and/or in commercial use based on data observations to date; the expected timepoint for additional readouts on efficacy data of BNT162b2 in our Phase 2/3 trial; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any potential Emergency Use Authorization; the timing for submission of manufacturing data to the FDA; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties. For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report on Form 20-F filed with the SEC on March 31, 2020, which is available on the SEC’s website at All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.

Comments - Make a comment
The comments are owned by the poster. We are not responsible for its content. We value free speech but remember this is a public forum and we hope that people would use common sense and decency. If you see an offensive comment please email us at
No Subject
Posted on: 2020-11-09 08:17:05   By: Anonymous
President Trump promised that there would be a vaccine in November and here it is. So for all of you Democrats that said it would never happen and continually trashed the President you can just GO TO HELL!

[Reply ]

    Posted on: 2020-11-09 08:33:48   By: Anonymous
    It isn’t “available”. You can’t go get vaccinated. Promising research though.

    [Reply ]

    Posted on: 2020-11-09 08:55:31   By: Anonymous
    I voted for Biden but it is fascinating that Pfizer chose to release this news AFTER the election. This is what happens when you dis science and medical professionals. The research community is done with Trump and moving forward. ps - Yes, great news but several months at least to go before it can be given to the general public and produced in needed quantity.

    [Reply ]

      Posted on: 2020-11-09 09:03:48   By: Anonymous
      Keep up the brain eating hate.

      [Reply ]

        Posted on: 2020-11-09 10:11:49   By: Anonymous

        [Reply ]

        Posted on: 2020-11-09 13:05:24   By: Anonymous
        Nope, that’s a good call. Payback’s a biatch, isn’t it Mr. tRump? Speaking of hate, am sure you’ll see the Twitter in Chief firing many in the next few weeks he’s deemed less than loyal.

        [Reply ]

          Posted on: 2020-11-09 17:03:15   By: Anonymous
          Hey just letting you know Calaveras county voted red and still has small town values can you take all your crazy ideas back to the Bay Area utopia you created. Thanks!

          [Reply ]

        Posted on: 2020-11-13 10:54:59   By: Anonymous
        Funny. Behind a beater truck in San Andreas yesterday with a hand-lettered cardboard sign tied to the bumper. It read “Your all terrorists for voting against democracy, etc.” Beyond the grammar, it was sad to see he or maybe she doesn’t understand about plurality and majority rule.

        [Reply ]

    Posted on: 2020-11-09 08:57:04   By: Anonymous
    Haven't you heard? Trump is yesterday's news. Biden is already in DC assembling the pandemic committee and more. Working from day one as promised, not traveling to golf courses.

    [Reply ]

      Posted on: 2020-11-09 09:06:23   By: Anonymous
      Soon he will need a vacation and be off to an island with trafficked children.

      [Reply ]

        Posted on: 2020-11-09 09:58:01   By: Anonymous
        Trump and Clinton were friends with Epstein and his dirty little island, not Biden.

        [Reply ]

          Posted on: 2020-11-09 10:12:51   By: Anonymous
          Trump banged 14 year olds

          [Reply ]

            Posted on: 2020-11-09 10:17:34   By: Anonymous


            [Reply ]

            Posted on: 2020-11-09 10:26:48   By: Anonymous
            Your dad got banged at the lube room parking lot years ago...

            [Reply ]

    Posted on: 2020-11-09 11:20:33   By: Anonymous
    Trumps relationship with Science in general.... Meh... not so much.

    This has nothing to do with him. And you know it.

    [Reply ]

    Re: Be Prepared For Democrats Crashing Our Economy
    Posted on: 2020-11-09 12:25:52   By: Anonymous
    Trump's done so many great things for America and her people, but because of his personality our bigoted Media hates him. He's even brought peace to most of the Mideast but no praise or even a mention from our Media. They couldn't even ask Joe or kamala any type of a question that was harder than, " What flavor of ice cream did you get?" Only once did some reporter ask about his son, Hunter, and his business deals and Biden became unhinged about it.
    Absolutely unbelievable.

    [Reply ]

      Re: Be Prepared For Democrats Crashing Our Economy
      Posted on: 2020-11-09 12:28:53   By: Anonymous
      Lol. Personality matters. Character matters. Facts matter.

      [Reply ]

      Absolutely unbelievable
      Posted on: 2020-11-09 13:13:05   By: Anonymous
      What's unbelievable is that you buy the Trump story every time.
      This vaccine has not gone through the full clinical trial yet.
      It will be months before the general public might be able to get it. That puts us into 2021. As many medical experts have predicted.
      Trump promised a vaccine before the election.
      Like most of his promises he has failed.
      Melania will be so glad to be rid of him.
      So will the majority of Americans.

      [Reply ]

      Re: Be Prepared For Democrats Crashing Our Economy
      Posted on: 2020-11-09 16:33:10   By: Anonymous
      Oh, please tell us those"great things"he has done, name some so we will know too.

      [Reply ]

No Subject
Posted on: 2020-11-09 08:32:16   By: Anonymous
Pfizer and BioNTech reported Monday that their Covid-19 vaccine is more than 90 percent effective in an early analysis.

—The results came in a press release, not a study
—They’re based on just 94 cases
—The clinical trial isn’t complete

[Reply ]

    Posted on: 2020-11-09 09:07:32   By: Anonymous
    No one cares, majority will not take it.

    [Reply ]

      Posted on: 2020-11-09 09:15:26   By: Anonymous
      Just remember - Biden had NOTHING to do with it but I'm sure he will take all the credit. Just like his campaign - He said he would do everything that Trump had already done. You people are in for a BIG surprise.

      [Reply ]

        Posted on: 2020-11-09 10:13:53   By: Anonymous

        [Reply ]

          Pense- Vaccine From Warp Speed- Pfizer Says Nope
          Posted on: 2020-11-09 11:38:48   By: Anonymous
          As usual, dump and pals try to steal credit for the Pfizer news.
          Pfizer says- nope, they did not take any $ , or worked with the broken FDA.

          Another example of grifter dump and his crew of liars, Pense this time caught in a lie.

          These clowns cannot be removed soon enough, donny is having a hissy fit tantrum , and eating tons of McDonalds according to those inside.

          He needs a time out, and his diaper changed.

          [Reply ]

        Posted on: 2020-11-09 13:09:22   By: Anonymous
        Most thinking individuals tend to dismiss any comments that include the words, “You people.”

        [Reply ]

No Subject
Posted on: 2020-11-09 17:00:56   By: Anonymous
If you have been watching the media cover all of the “Biden Celebrations” they don’t mention coronavirus even once. Why do we need a vaccine? Apparently coronavirus is gone woohoo! Superspreader events don’t exist anymore haha

[Reply ]

    Posted on: 2020-11-09 17:38:24   By: Anonymous
    That's right. If you are celebrating Sloppy Joe then you don't need a mask. This phony President-Elect is such a hypocritical piece of sh*t. He shows everyone that he supports social distancing on camera then as this pervert leaves the stage then it is off with the masks and the celebration begins.

    [Reply ]

No Subject
Posted on: 2020-11-09 17:48:15   By: Anonymous
Currently, the Covid-19 virus epidemic is still raging in many countries around the world causing serious impacts, the fact that you have such a positive signal is good news for everyone. Hopefully it will be completed soon to cure everyone. Please visit my website puzzle jigsaw

[Reply ]

What's Related
These might interest you as well
Local News


Photo Albums

phpws Business Directory

RSS News Feeds

Web Pages

Mark Twain Medical Center
Meadowmont Pharmacy
Bank of Stockton
Bear Valley Real Estate
Bear Valley Cross Country
Cedar Creek Realty
Cave, Mine & Zip Lines
Fox Security
Bistro Espresso
Pinnacle Physical Therapy
Chatom Winery
Middleton's Furniture
Bear Valley Mountain Resort
Paul D. Bertini
Premier Properties
High Country Spa & Stove
Calaveras Mentoriing

Ebbetts Pass Scenic Byway
Sierra Logging Museum
Jenny's Kitchen

Copyright © The Pine Tree 2005-2020